G. Surendra Reddy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
G. Surendra Reddy has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Dhevalapally Buchi Ramachary
Catalysis Laboratory, School of Chemistry, University of Hyderabad, Hyderabad-500 046, India
2 shared publications - Jagjeet Gujral
Catalysis Laboratory School of Chemistry University of Hyderabad 500 046 Hyderabad‐ India
2 shared publications - Swamy Peraka
Catalysis Laboratory, School of Chemistry University of Hyderabad Hyderabad 500 046 India
2 shared publications Aditya Bansal
Division of Nuclear Medicine Department of Radiology, Mayo Clinic Rochester MN 55905 USA
1 shared publicationGeoffry L. Curran
Division of Nuclear Medicine Department of Radiology, Mayo Clinic Rochester MN 55905 USA
1 shared publicationHeather M. Stein
Division of Nuclear Medicine Department of Radiology, Mayo Clinic Rochester MN 55905 USA
1 shared publication
Latest Publications
- 28 December 2022
- Published by Wiley in European Journal of Organic Chemistry
- Vol. 26 (3)
Comparison of [18F]F‐CNBI and [18F]F‐CNPIFE as Positron Emission Tomography Probes for Noninvasive Imaging of Glycogen Synthase Kinase‐3 in Normal Mice
Glycogen synthase kinase‐3 α/β is involved in dysregulation of neuronal tau protein in Alzheimer's disease (AD). There is an unmet clinical need for a blood‐brain barrier (BBB) permeable positron emission tomography (PET) probe for imaging of GSK‐3α/β in the brain to understand the pathogenesis of AD. Herein, we synthesized two PET probes, [18F]F‐CNBI and [18F]F‐CNPIFE, and evaluated their BBB permeability and affinity towards GSK‐3α/β. [19F]F‐CNPIFE showed higher in‐vitro binding towards GSK‐3α/β (IC50=19.4±2.5 nM; n=3, for GSK‐3α, IC50=19.4±3.8 nM; n=3, for GSK‐3β) compared to [19F]F‐CNBI (IC50=107.6±26.0 nM; n=4, for GSK‐3α, IC50=105.3±18.2 nM; n=3, for GSK‐3β). [18F]F‐CNPIFE showed 9.5‐fold higher brain uptake than [18F]F‐CNBI, in normal FVB/NJ mice, which was increased by additional 1.5‐fold on co‐administration of [19F]F‐CNPIFE with respect to [18F]F‐CNBI. Overall, [18F]F‐CNPIFE is a promising PET probe for GSK‐3α/β imaging and warrants further evaluation in an AD mouse model.
- 28 December 2022
- Published by Wiley in European Journal of Organic Chemistry
- Vol. 26 (3)
Comparison of [18F]F‐CNBI and [18F]F‐CNPIFE as Positron Emission Tomography Probes for Noninvasive Imaging of Glycogen Synthase Kinase‐3 in Normal Mice
Glycogen synthase kinase‐3 α/β is involved in dysregulation of neuronal tau protein in Alzheimer's disease (AD). There is an unmet clinical need for a blood‐brain barrier (BBB) permeable positron emission tomography (PET) probe for imaging of GSK‐3α/β in the brain to understand the pathogenesis of AD. Herein, we synthesized two PET probes, [18F]F‐CNBI and [18F]F‐CNPIFE, and evaluated their BBB permeability and affinity towards GSK‐3α/β. [19F]F‐CNPIFE showed higher in‐vitro binding towards GSK‐3α/β (IC50=19.4±2.5 nM; n=3, for GSK‐3α, IC50=19.4±3.8 nM; n=3, for GSK‐3β) compared to [19F]F‐CNBI (IC50=107.6±26.0 nM; n=4, for GSK‐3α, IC50=105.3±18.2 nM; n=3, for GSK‐3β). [18F]F‐CNPIFE showed 9.5‐fold higher brain uptake than [18F]F‐CNBI, in normal FVB/NJ mice, which was increased by additional 1.5‐fold on co‐administration of [19F]F‐CNPIFE with respect to [18F]F‐CNBI. Overall, [18F]F‐CNPIFE is a promising PET probe for GSK‐3α/β imaging and warrants further evaluation in an AD mouse model.
- 28 December 2016
- Published by Wiley in European Journal of Organic Chemistry
- Vol. 2017 (3) , 459-464
Triazabicyclodecene as an Organocatalyst for the Regiospecific Synthesis of 1,4,5‐Trisubstituted N‐Vinyl‐1,2,3‐triazoles
Herein we report on the 1,5,7‐triazabicyclo[4.4.0]dec‐5‐ene (TBD) catalyzed enolate‐mediated regiospecific synthesis of 1,4,5‐trisubstituted N‐vinyl‐1,2,3‐triazoles from simple activated carbonyl compounds and N‐vinyl azides through [3+2] cycloaddition; upon further hydrogenation, 1,4,5‐trisubstituted N‐alkyl‐1,2,3‐triazoles are furnished. Both the organo‐click and hydrogenation reactions proceeded in excellent yields with high rates and selectivities at 25 °C within a few hours.
- 28 December 2016
- Published by Wiley in European Journal of Organic Chemistry
- Vol. 2017 (3) , 459-464
Triazabicyclodecene as an Organocatalyst for the Regiospecific Synthesis of 1,4,5‐Trisubstituted N‐Vinyl‐1,2,3‐triazoles
Herein we report on the 1,5,7‐triazabicyclo[4.4.0]dec‐5‐ene (TBD) catalyzed enolate‐mediated regiospecific synthesis of 1,4,5‐trisubstituted N‐vinyl‐1,2,3‐triazoles from simple activated carbonyl compounds and N‐vinyl azides through [3+2] cycloaddition; upon further hydrogenation, 1,4,5‐trisubstituted N‐alkyl‐1,2,3‐triazoles are furnished. Both the organo‐click and hydrogenation reactions proceeded in excellent yields with high rates and selectivities at 25 °C within a few hours.
- 7 December 2016
- Published by Wiley in ChemCatChem
- Vol. 9 (2) , 263-267
Organocatalytic Vinyl Azide‐Carbonyl [3+2] Cycloaddition: High‐Yielding Synthesis of Fully Decorated N‐Vinyl‐1,2,3‐Triazoles
For the first time, an enolate‐mediated organocatalytic vinyl azide‐carbonyl [3+2] cycloaddition (OrgVACC) of various ketones/aldehydes with vinyl azides is reported. It is an efficient intermolecular reaction with excellent outcomes with reference to rate, yield, selectivity, operational simplicity, substrate scope, catalyst simplicity, and vast applications.
- 7 December 2016
- Published by Wiley in ChemCatChem
- Vol. 9 (2) , 263-267
Organocatalytic Vinyl Azide‐Carbonyl [3+2] Cycloaddition: High‐Yielding Synthesis of Fully Decorated N‐Vinyl‐1,2,3‐Triazoles
For the first time, an enolate‐mediated organocatalytic vinyl azide‐carbonyl [3+2] cycloaddition (OrgVACC) of various ketones/aldehydes with vinyl azides is reported. It is an efficient intermolecular reaction with excellent outcomes with reference to rate, yield, selectivity, operational simplicity, substrate scope, catalyst simplicity, and vast applications.